Evidence map›Paper›PMID 40736454›Full record

SynthesisCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025

Racial and Ethnic Disparities in Survival among Patients with Cholangiocarcinoma in the United States: A Systematic Review and Meta-analysis.

Andrew D Shubin, Phillip J Leff, Meena M Tadros, Meng L Hsieh, David Hsiehchen, Parsia A Vagefi, Jason Y Wang, Gonzalo Sapisochin, Adam C Yopp, Nina N Sanford and 4 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Andrew D Shubin *Division of Surgical Transplantation, Department of Surgery, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-5506-8772
Phillip J Leff *Department of Internal Medicine, Creighton University, Omaha, Nebraska.ORCID 0009-0009-7379-7579
Meena M TadrosSchool of Medicine, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-9755-0751
Meng L HsiehDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-6360-005X
David HsiehchenDivision of Hematology Oncology, Department of Internal Medicine UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-9139-302X
Parsia A VagefiDivision of Surgical Transplantation, Department of Surgery, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-0461-5438
Jason Y WangSchool of Medicine, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-3829-1539
Gonzalo SapisochinDivision of Abdominal Transplant Surgery, Department of Surgery, University Health Network, Toronto, Canada.ORCID 0000-0001-9527-8723
Adam C YoppDivision of Surgical Oncology, Department of Surgery, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-5887-5315
Nina N SanfordDepartment of Radiation Oncology, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-7840-5700
Ju Dong YangKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0001-7834-9825
Amit G SingalDivision of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-1172-3971
Madhukar S Patel *Division of Surgical Transplantation, Department of Surgery, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-7508-899X
Nicole E Rich *Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-2740-8818

Funding

Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinomaR01MD012565 · NIMHD · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT, YOPP, ADAM · 2018 to 2022
$4.3M
Multi-level Evaluation of Racial/ethnic Disparities in Liver Disease OutcomesR01CA256977 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KANWAL, FASIHA, SINGAL, AMIT · 2021 to 2025
$3.0M
Determining the influence of sex and gender in hepatocellular carcinoma risk and survivalK08CA259536 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Nicole Elizabeth Rich · 2022 to 2026
$1.3M
Glycan Biomarkers for CholangiocarcinomaR01CA289381 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Anand S. Mehta · 2025 to 2026
$1.3M
American College of Gastroenterology (ACG) Junior Faculty Development AwardNCI NIH HHS K08 CA259536NCI NIH HHS R01 CA256977NCI NIH HHS R01 CA289381NIMHD NIH HHS R01 MD012565
6 · The paper itself

Abstract

backgroundCholangiocarcinoma (CCA) is an increasing cause of mortality in the United States; however, the burden of CCA disproportionately affects racial and ethnic minority groups. We aimed to characterize racial and ethnic differences in stage, treatment, and survival among patients with CCA.

methodsWe systematically searched MEDLINE and Embase through March 2023 for all studies reporting clinical outcomes among patients with CCA stratified by race and ethnicity. We calculated pooled HRs using the DerSimonian and Laird method for a random-effects model.

resultsOf 292 articles, 16 met inclusion criteria (n = 248,109 patients). Among six studies (n = 87,938) reporting overall survival, Black patients had worse survival [pooled HR, 1.05; 95% confidence interval (CI), 1.01-1.10], whereas Hispanic (pooled HR, 0.86; 95% CI, 0.83-0.89) and Asian/Pacific Islander (pooled HR, 0.88; 95% CI, 0.85-0.90) patients had better survival than White patients. Compared with White patients, Black and Hispanic patients were less likely to present at an early stage, and Black patients were less likely to undergo resection (pooled OR, 0.69; 95% CI, 0.63-0.75). The limitations of studies were lack of granularity on subtype and risk of residual confounding.

conclusionsThere are racial and ethnic differences in CCA prognosis in the United States, with Black patients having worse survival and Hispanic and Asian patients having better survival than White patients. Studies are needed to identify actionable factors underlying this disparity to promote health equity and improve outcomes for patients. IMPACT: There exist racial discrepancies in survival and treatment for CCA; more studies are needed to better understand the extent and causes of discrepancies.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaEthnicityHealth Status DisparitiesRacial GroupsHealthcare DisparitiesHumansUnited States

Identifiers

PMID40736454
PMCPMC12507172

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.